Drugs · acquisition-cost intelligence
CARBZAH
Carbinoxamine Maleate· ingredient carbinoxamine· CARBINOXAMINE MALEATE 4 mg/1; CARBINOXAMINE MALEATE 4 mg/5mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.42965
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-06-182026-05-20
Same-ingredient options by acquisition cost
Other carbinoxamine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Carbinoxamine Maleate | $0.42965 | +$0.00000 |
| Carbinoxamine Maleate Extended-Release Oral Suspension | $1.12 | +$0.69070 |
Medicare Part D coverage · CY2026
On 20 plan formularies · typical tier 1
Prior auth 75% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.